Frank - Griesinger

• Research Director at Carl von Ossietzky University of Oldenburg

Background Osi, a 3rd-generation, central nervous system-active, EGFR-TKI, is the preferred 1L tx for EGFRm advanced NSCLC. We report interim results from a German cohort of a global rw prospective, observational study of long-term survival and tx patterns in pts with EGFRm advanced NSCLC who received 1L osi. Methods Data for pts aged ≥18 yrs with...

Background EGFR tyrosine kinase inhibitors (TKIs) are the standard 1L treatment for pts with advanced NSCLC with EGFR mutations (EGFRm). Osimertinib is a third-generation, irreversible EGFR TKI that selectively inhibits sensitizing and T790M mutations, and is effective in NSCLC central nervous system metastases. In this global rw study, an interim...

Background: Patients (pts) with lung cancer under treatment have been associated with a high risk of COVID-19 infection and potentially worse outcome, but real-world data on patient-reported outcomes (PRO) are still scarce. We show pts’ characteristics and PRO before and during the COVID-19 pandemic in a representative advanced non-small cell lung...

Background RET fusions are present in 1%–2% of non-small cell lung cancer (NSCLC). Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective RET inhibitor, previously demonstrated clinical activity in patients with RET fusion–positive NSCLC in the phase I/II ARROW study, including among treatment-naïve patients. We report an u...

Background: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial. Pati...

Purpose/Objective(s) In VISION Cohort A, tepotinib showed robust and durable clinical activity in pts with METex14 skipping NSCLC. Here, we present biomarker analyses on serial LBx samples. Materials/Methods LBx samples at baseline (BL), Week 6, 12, and end of treatment (EOT) were analyzed (73 genes). Investigator (INV)-assessed clinical outcome w...

Background At the primary data cut-off, the ALUR study demonstrated significantly improved progression-free survival (PFS) and central nervous system (CNS) objective response rate (ORR) with alectinib versus chemotherapy in pretreated, advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer. We report final efficacy and safety...

Background Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC). We aimed to evaluate in this investigator-initiated study the predictive utility of the mRNA expression levels of ERCC1 and TS as assessed in resected tumor. Methods Seven hundred sev...

Immune related endonucleases have recently been described as potential therapeutic targets and predictors of response to treatment with immune checkpoint inhibitors (ICI). The aim is to evaluate the association between the expression of 5 biomarkers involved in the immune response (CD73, CD39, VISTA, Arl4d and Cytohesin-3) in parallel with the more...

Background: Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD-SCLC), with 5-year overall survival (OS) of only 25-33%. Methods: STIMULI is a 1:1 randomised phase II trial aiming to demonstrate superiority of consolidation co...

Objective Panel-based next-generation sequencing (NGS) is increasingly used for the diagnosis ofEGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk assessment in combination with clinical parameters. Materials and methods : To this end, we retrospectively analyzed the outcome of 400 tyrosine kinase inhibitor (TKI)-treated EGFR⁺...

Background In the first preplanned interim analysis (IA) from ALTA-1L (NCT02737501; median follow-up BRG/CRZ: 11.0/9.3 mo, 99 PFS events), BRG demonstrated superior BIRC-assessed PFS and improved patient-reported quality of life vs CRZ. We report results of the second IA planned at 75% of 198 expected events. Methods Patients (pts) with ALK inhibi...

Background Guidelines for metastatic non-small cell lung cancer recommend stratified treatment by biomarker test results. We used CRISP to evaluate treatment and outcome of patients (pts) with targetable molecular alterations. Methods Currently 163 sites in Germany have recruited >3700 pts at start of 1st-line who will be followed until death or e...

Background EGFR-TKIs are the preferred 1L therapy for pts with EGFRm metastatic NSCLC. However, treatment and survival in this population with 2L therapy and beyond are not well defined in the RW setting. To address this, we analysed RW cohort data in the USA, UK, Germany and France. Methods A retrospective chart review was conducted for 472 pts w...

Background Treatment guidelines for metastatic non-small cell lung cancer recommend stratified treatment according to biomarker testing results. Here we used CRISP to evaluate treatment and outcome of patients (pts) with PD-L1-expressing tumors. Methods Currently 163 centers in Germany have recruited over 3700 pts at start of 1st-line who will be...

Background Brigatinib is a next-generation ALK inhibitor with activity against a broad range of ALK mutations and ROS1 rearrangements. It is approved for use post-crizotinib in ALK+ mNSCLC based on phase II trial (ALTA) data, and significantly improved progression-free survival (PFS) vs crizotinib (HR = 0.49) in ALK TKI-naïve patients (pts) in the...

Background The presence of brain metastases is a negative prognostic factor for non-small cell lung cancer (NSCLC) patients, which are therefore frequently excluded from clinical trials. A competing risk analysis from the Lux Lung trials showed that afatinib delayed the onset/progression of brain metastases. In Lux Lung 3 patients with brain metast...

Background The percentage of pts switching from 1st gen TKI in 1st line to 3rd gen TKI in 2nd line seems to be low with 30% and it is questionable whether these data represent real world treatments. Therefore, we investigated the treatment pattern and especially the attrition rate between 1st and 2nd line therapy in EGFR mt+ pts from the NOWEL netw...

Background Guidelines for metastatic non-small cell lung cancer recommend stratified treatment by biomarker test results. We used CRISP to evaluate treatment and outcome of patients (pts) in whom neither targetable molecular alterations nor any PD-L1 expression were detected. Methods Currently 163 sites in Germany have recruited >3700 pts at start...